15:I[66739,["/_next/static/chunks/0_jglizaxuvid.js?dpl=dpl_3DD9m2VJCfF4backj8XFu57cygkx","/_next/static/chunks/00yc4h63rurg4.js?dpl=dpl_3DD9m2VJCfF4backj8XFu57cygkx","/_next/static/chunks/01b21njbdx~~m.js?dpl=dpl_3DD9m2VJCfF4backj8XFu57cygkx","/_next/static/chunks/14s118kzsmuz9.js?dpl=dpl_3DD9m2VJCfF4backj8XFu57cygkx","/_next/static/chunks/166.u_60qj09..js?dpl=dpl_3DD9m2VJCfF4backj8XFu57cygkx","/_next/static/chunks/0g9_wl34k-6l4.js?dpl=dpl_3DD9m2VJCfF4backj8XFu57cygkx","/_next/static/chunks/0~r4f.cjjsl~b.js?dpl=dpl_3DD9m2VJCfF4backj8XFu57cygkx"],"default"] 17:I[38632,["/_next/static/chunks/0qqtp3r0h7kah.js?dpl=dpl_3DD9m2VJCfF4backj8XFu57cygkx","/_next/static/chunks/0iukvycbd42rl.js?dpl=dpl_3DD9m2VJCfF4backj8XFu57cygkx"],"IconMark"] 16:T545,

Eli Lilly (LLY) shares dropped after its latest earnings report and disappointing results for an oral GLP-1 pill. Lee Brown joins Sam Vadas to discuss the phase 3 trial and says "the markets missing the big picture here" believing "tolerability" is the key focal point. He points to the differences in Novo Nordisk (NVO) and LLY weight-loss drug offerings. Lee dives into Mounjaro's cardio-protective results as well, saying it might be "overlooked" in today's report.

======== Schwab Network ========

Empowering every investor and trader, every market day.

Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribe

Download the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185

Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7

Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watch

Watch on Vizio - https://www.vizio.com/en/watchfreeplus-explore

Watch on DistroTV - https://www.distro.tv/live/schwab-network/

About Schwab Network - https://schwabnetwork.com/about

LLY Tops Earnings, Stock Sheds Weight on Disappointing GLP-1 Pill Trial

Schwab Network

LLY Tops Earnings, Stock Sheds Weight on Disappointing GLP-1 Pill Trial